Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with
hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) …

Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …

Patients with hematological malignancy and COVID-19 display a high mortality rate. In such
patients, immunosuppression due to underlying disease and previous specific treatments …

To the Editor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has
caused high mortality in patients with hematological malignancies (HM). 1 The newly …

Prolonged Covid‐19 is an emerging issue for patients with lymphoma or immune deficiency.
We aimed to examine prolonged length of in‐hospital stay (LOS) due to Covid‐19 among …

Background Post-transplant cyclophosphamide (PT-Cy) has become a standard of care in
haploidentical hematopoietic stem cell transplantation (HSCT) to reduce the risk of graft-…

Background Patients with lymphoma are immunocompromised because of the disease per
se and its treatments. We aimed to describe the characteristics of patients with lymphoma …

Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in
immunocompetent patients with COVID-19, but data on efficacy in patients with haematological …

Although post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease
(GVHD) prophylaxis, it is associated with toxicities, which might be dose-dependent. We …